- Home
- CRBP vs NMT Comparison
CRBP vs NMT Comparison
Compare CRBP & NMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- NMT
- Stock Information
- Founded
- CRBP 2009
- NMT 1993
- Country
- CRBP United States
- NMT United States
- Employees
- CRBP N/A
- NMT N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- NMT Finance/Investors Services
- Sector
- CRBP Health Care
- NMT Finance
- Exchange
- CRBP Nasdaq
- NMT Nasdaq
- Market Cap
- CRBP 96.5M
- NMT 109.0M
- IPO Year
- CRBP N/A
- NMT N/A
- Fundamental
- Price
- CRBP $8.22
- NMT $11.75
- Analyst Decision
- CRBP Strong Buy
- NMT
- Analyst Count
- CRBP 10
- NMT 0
- Target Price
- CRBP $53.56
- NMT N/A
- AVG Volume (30 Days)
- CRBP 214.0K
- NMT 19.1K
- Earning Date
- CRBP 08-05-2025
- NMT 01-01-0001
- Dividend Yield
- CRBP N/A
- NMT 3.21%
- EPS Growth
- CRBP N/A
- NMT N/A
- EPS
- CRBP N/A
- NMT N/A
- Revenue
- CRBP N/A
- NMT N/A
- Revenue This Year
- CRBP N/A
- NMT N/A
- Revenue Next Year
- CRBP $150.03
- NMT N/A
- P/E Ratio
- CRBP N/A
- NMT N/A
- Revenue Growth
- CRBP N/A
- NMT N/A
- 52 Week Low
- CRBP $4.64
- NMT $9.05
- 52 Week High
- CRBP $61.90
- NMT $10.93
- Technical
- Relative Strength Index (RSI)
- CRBP 54.23
- NMT 47.66
- Support Level
- CRBP $7.26
- NMT $11.61
- Resistance Level
- CRBP $7.90
- NMT $11.88
- Average True Range (ATR)
- CRBP 0.53
- NMT 0.10
- MACD
- CRBP -0.01
- NMT 0.01
- Stochastic Oscillator
- CRBP 78.59
- NMT 56.45
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.